Kyowa Hakko Kirin, Medgenics deal

Kyowa granted Medgenics an exclusive option to license exclusive rights in the U.S. and Canada to develop and commercialize an undisclosed mAb against tumor necrosis factor (TNF) ligand superfamily member 14 ( TNFSF14; LIGHT; CD258). The option is exercisable upon completion of a signal finding study in severe pediatric onset inflammatory bowel disease (IDB); data are expected 1H17.

If the option is exercised, Kyowa will receive an upfront cash payment in the low single-digit millions and grant Medgenics commercialization rights in pediatric IBD and other rare and Orphan pediatric diseases. Following the exercise, Kyowa will have 60 days to select a co-development/co-commercialization partnership or a licensing structure. ...